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A B S T R A C T
In order to determine possible differences in serum gangliosides content and composition before and after surgical re-
moval of tumor, gangliosides isolated from preoperative and postoperative sera of patients with brain tumors were ana-
lyzed. Serum samples were collected from patients with glioblastoma, meningioma, acoustic neurinoma, haemangioma,
oligodendroglioma and astrocytoma, one week before and one week after surgical removal of the tumor. Serum gan-
gliosides were qualitatively and quantitatively analyzed by high performance thin layer chromatography and laser
densitometry. Results showed changes of total gangliosides concentrations in analyzed postoperative sera comparing to
preoperative sera. There was not a significant difference in ganglioside pattern of preoperative vs. preoperative sera.
However, a postoperative decreased proportion of ganglioside GD3 was observed in sera derived from patients with com-
plete tumor removal. The results of this study indicate that comparative quantitative and compositional analysis of both
preoperative and postoperative serum gangliosides may provide useful information concerning tumor progression, sur-
gical success and prognosis.
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Introduction
Gangliosides (GG) are important lipid constituents of
cell membranes1. Chemically, gangliosides are glycosphi-
ngolipids containing sialic acids (SA) and are particularly
abundant in membrane microdomains considered as
highly organized units with various specific functions2.
Gangliosides are involved in many significant cellular
processes such as cell growth, cell proliferation, differen-
tiation, oncogenic transformation, etc3. Animal brain tis-
sue is highly enriched in gangliosides – phylogenetic and
ontogenetic differences in brain ganglioside biosynthesis
have been evidenced as well as regional distribution and
specific ganglioside patterns characterizing neuronal and
glial cells during brain development, aging and neuro-
degeneration4–7. Specific changes of gangliosides pattern
in brain tumors reflecting tumor histopathological ori-
gin, malignancy and progression, have been extensively
studied8–12. Also, it has been observed that tumor cells of
neuroectodermal origin may shed their gangliosides into
circulation, resulting in higher ganglioside concentra-
tions in serum13,14. This shedding of gangliosides into in-
terstitial spaces and blood of oncological patients has
been suggested to be involved in increased tumor cell
growth and lack of immune cell recognition14. Although
many studies have consistently reported higher concen-
trations of serum gangliosides in oncological patients
comparing to healthy individuals, there have been no
data on comparison of ganglioside concentrations in se-
rum before and after surgical removal of tumor in indi-
vidual patients13,15,16. The aim of this study was to trace
possible differences between preoperative and postopera-
tive concentrations of serum gangliosides in patients
with brain tumors and to estimate a potential prognostic
value of these differences.
Material and Methods
Material
Blood samples (5–10 mL) were collected from individ-
uals with no evidence of neurological or oncological dis-
ease (N=10), and patients with diagnosis of glioblastoma
(N=3), meningioma (N=3), acoustic neurinoma (N=1),
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haemangioma (N=1), oligodendroglioma (N=1) and as-
trocytoma (N=1), one week before and one week after
surgical removal of the tumor. In control group of 10 vol-
unteers, there were 4 females and 6 males in age range
from 23 to 75 years. Group of patients consisted of 4
males and 6 females in age range from 22 to 76 years.
Clinical diagnosis and localization of brain tumors were
determined using computerized tomography (CT) and
magnetic resonance (MR), followed by final pathohis-
tological analysis of postoperative tumor tissue. Serum
was isolated from the whole blood by routine laboratory
method, i.e. blood was collected in tubes containing anti-
coagulants and serum was finally separated from plasma
and blood cells by centrifugation.
Biochemical analysis of serum gangliosides
Ganglioside extraction and purification was perfor-
med according to the method of Svennerholm17. Extrac-
tion and reextraction steps used chloroform (C), metha-
nol (M) and water (W) in a final volume ratio 1:1:0.8
(C:M:W, v/v/v). Upper phases containing polar ganglio-
sides were collected and air-dried, and obtained dry gan-
glioside extract was finally purified by dialysis (over-
night, 4 °C). Purified ganglioside extract was used for
quantitative and qualitative analysis of gangliosides.
Qualitative analysis of serum gangliosides was per-
formed by high performance thin layer chromatographic
(HPTLC) separation of individual gangliosides on silica
gel plates. The samples of purified ganglioside extracts
derived from patients and pooled control sera were dis-
solved in chloroform:methanol (1:1) and applied to the
HPTLC plates. Also, three standard mixtures of gan-
gliosides were applied to the HPTLC plates: (a) a range
of concentrations of Cronassial ganglioside mixture (3, 5
and 9 micrograms of GG-SA per lane); (b) GM2 ganglio-
side from the human lung tissue; (c) ganglioside mixture
derived from the human cerebellar tissue, prepared and
purified in our laboratory. The plates were developed in a
solvent system containing chloroform, methanol and 12
mM MgCl2 (58:40:9, v/v/v). After drying, plates were
sprayed with resorcinol reagent and heated during 30–45
minutes until the visualization of ganglioside fractions
which appeared as bluish bands. Finally, HPTLC plates
with separated and visualized ganglioside fractions were
analyzed by laser densitometry (LKB 2202 Laser Ul-
trascan) at 580 nm. Laser densitometry enabled direct
quantification of total gangliosides, according to the me-
thod of Trbojevi}-^epe et al18. The total concentrations of
gangliosides were expressed as nanomoles of ganglio-
side-bound sialic acids (GG-SA) in milliliter of serum.
Densitometric quantification of individual gangliosides
in each sample was expressed as their relative proportion
(%) in a sample. Abbreviations used for designation of
the individual ganglioside species are in accordance with
the accepted system of Svennerholm19 and the recommen-
dations of IUPAC-IUB Commission on Biochemical No-
menclature20,21.
Results and Discussion
Total ganglioside concentrations in sera
derived from patients with brain tumors
In this study, total ganglioside concentrations were de-
termined in serum samples derived from 10 patients with
different types of brain tumors and 10 individuals with no
evidence of oncologic disease, as shown in Table 1. Deter-
mined values were in a range from 1.68 to 14.37 nmol
GG-SA/mL. Such a high variation of total serum gan-
glioside concentrations among individuals has been also
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TABLE 1
COMPARISON OF GANGLIOSIDE CONCENTRATIONS IN PREOPERATIVE AND
POSTOPERATIVE SERA DERIVED FROM PATIENTS WITH BRAIN TUMORS
Diagnosis Surgery outcome
Preoperative serum gangliosides
(nmol GG-SA/mL)
Postoperative serum gangliosides
(nmol GG-SA/mL)
Meningioma 1
Complete removal
of the tumor
9.45 2.23
Meningioma 2 13.91 4.92
Meningioma 3 3.07 2.04
Acoustic neurinoma 7.57 7.47
Haemangioma
Partial removal of
the tumor
14.37 10.16
Glioblastoma 1 1.68 4.24
Glioblastoma 2 2.81 7.96
Glioblastoma 3 2.59 n. d.
Oligodendroglioma 3.14 n. d.
Astrocytoma 2.13 3.46
Control
(range:
serum
nmol GG-SA/mL)
gangliosides
Healthy individuals (N=10) 5.8 – 6.3
GG-SA, ganglioside-bound sialic acid; n. d., not determined.
reported by other authors22. Although total ganglioside
concentrations in patients’ sera were within a control
range, clear differences between preoperative and post-
operative sera were observed. Moreover, it seems that
surgical outcome i.e. complete or partial tumor removal
influenced the trend of postoperative ganglioside concen-
tration changes. Figure 1a shows postoperative decrease
of serum ganglioside concentrations in patients in which
tumor was completely removed (meningioma, acoustic
neurinoma, haemangioma) (mean values: 9.67 nmol GG-
-SA/mL preoperatively vs. 5.36 nmol GG-SA/mL postop-
eratively). This finding is in accordance with generally
accepted explanation that increase of total ganglioside
concentrations in serum of oncological patients origi-
nates from ganglioside production and secretion/shed-
ding by tumor tissue13,14. On the other hand, in the case
of partial tumor removal (glioblastoma, astrocytoma,
oligodendroglioma), concentrations of serum gangliosi-
des increased postoperatively (mean values: 2.47 nmol
GG-SA/mL preoperatively vs. 5.22 nmol GG-SA/mL post-
operatively), as represented in Figure 1b. It has to be
pointed out that all these partially removed tumors were
of much higher malignancy comparing to the group of
completely removed tumors. Thus, patients bearing mo-
re malignant types of brain tumors were treated by
aggressive radiotherapy which, apart from having immu-
nosuppressive effects, could also influence a liver metab-
olism of circulating gangliosides. This intriguing result
indicates potential relevance of gangliosides as biomar-
kers of a surgical outcome.
According to our knowledge, this is the first study in-
cluding the analysis of postoperative sera in order to
compare differences between serum ganglioside concen-
trations before and after surgical treatment in individual
patients. This study, showing clear differences between
preoperative vs. postoperative sera, indicates the poten-
tial prognostic value of serum ganglioside determination
in patients with brain tumors. However, a larger study
and longer postoperative follow-up is needed in order to
characterize the exact relation of serum ganglioside con-
centrations to surgical outcome.
Ganglioside composition in preoperative and
postoperative sera derived from patients with
brain tumors
Qualitative analysis of ganglioside pattern in patie-
nts’ and control sera, using high performance thin layer
chromatography, showed in all tested samples the frac-
tions migrating as GT1b, GD1a, GD3, GM2 and GM3
(Figure 2). GD3 and GM3 were found to be the most
abundant ganglioside species in all analyzed serum sam-
ples, which is common finding for ganglioside pattern of
extraneural tissues23. Several unknown minor fractions
with migrating properties of disialoganglioside and mo-
nosialoganglioside structures were also observed in both
patients’ and control sera. Possible candidate structures
with HPTLC-migration properties of monosialylated spe-
cies are GM1a, GM1b, LM1 and nLM1, while those mi-
grating as a reference disialo-species are GD1a, LD1 and
nLD1 (and their isomers). Since ganglioside pattern in
normal human serum has not yet been systematically
and reliably analyzed, our further investigation will fo-
cus on the elucidation of serum ganglioside structures
using highly sensitive mass spectrometry methods.
Chromatographically separated ganglioside patterns
of normal serum as well as preoperative and postopera-
tive serum did not reveal significant differences (Figure
2). However, a quantification of individual serum gan-
gliosides by laser densitometric analysis showed that in
all patients with completely removed tumor (menin-
gioma, acoustic neurinoma, haemangioma) there was a
postoperative decrease of GD3 proportion and increase
in GM3 proportion (Figure 3). The most prominent post-
operative decrease of GD3 proportion was observed in
the case of haemangioma and meningioma, which is con-
sistent with the postoperative decrease of corresponding
total serum ganglioside concentrations (Table 1). In the
case of partial tumor removal (glioblastoma and astro-
cytoma), such a change in postoperative GD3 and GM3
proportion was not so obvious. Since GM3 is a direct
biosynthetic precursor of GD3, change in GM3/GD3 ratio
in serum directly reflects alteration of tumor ganglioside
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Fig 1. Comparison of total gangliosides concentrations in preop-
erative and postoperative sera in cases of a) complete tumor re-
moval and b) partial tumor removal. GG-SA, ganglioside-bound
sialic acid.
metabolism. In addition, analyzing the ganglioside pat-
terns of corresponding tumor tissues of here selected pa-
tients we indeed observed higher proportion of GD3 and
GD2 as well as several additional fractions which need to
be structurally characterized; detailed structural identi-
fication is being currently conducted using reliable in-
strumental methods (data to be published). Simplifica-
tion of ganglioside pattern and increased GD3 proportion
in both tumor tissue and serum has been previously re-
ported and observed to be in relation with glioma ma-
lignancy13. Also, increased GD3 concentrations were fo-
und in serum and cerebrospinal fluid of patients with
meningioma, medulloblastoma and astrocytoma24,25.
The results of this study demonstrate that compo-
sitional analysis of serum gangliosides could provide ad-
ditional data on serum ganglioside alterations with po-
tential diagnostic relevance. However, employment of
more sensitive methods such as mass spectrometry would
ensure much deeper insight into compositional changes
of serum gangliosides particularly concerning minor spe-
cies not detectable by conventional analysis.
In conclusion, the results of this study indicate that
comparative quantitative and compositional analysis of
both preoperative and postoperative serum gangliosides
may provide useful information concerning tumor pro-
gression, surgical success and prognosis.
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Fig. 3. Relative proportion of GD3 and GM3 in preoperative vs.
postoperative sera derived from patients with brain tumors, as
quantified by laser densitometric analysis of gangliosides sepa-
rated by high performance thin layer chromatography. Data for
glioblastoma and meningioma represent mean values of three
analyzed samples.
Fig. 2. Ganglioside composition of analyzed serum samples as
revealed by high performance thin layer chromatographic sepa-
ration of individual gangliosides. a) Gangliosides in control hu-
man serum; a, b and c – Cronassial standard mixture of gan-
gliosides; d – GM1 ganglioside; e – GM3 ganglioside; f and g –
control serum samples. b) Serum gangliosides in patients with
brain tumors; a – Cronassial standard mixture of gangliosides; b
– GM2 ganglioside; c – gangliosides extracted from human cere-
bellum; d – glioblastoma preoperative serum; e – glioblastoma
postoperative serum; f – meningioma preoperative serum; g – me-
ningioma postoperative serum.
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SERUMSKI GANGLIOZIDI U PACIJENATA S MO@DANIM TUMORIMA
S A @ E T A K
U ovom radu analizirani su gangliozidi izolirani iz preoperativnih i postoperativnih seruma pacijenata s mo`danim
tumorima, kako bi se utvrdile mogu}e razlike u sadr`aju i sastavu serumskih gangliozida prije i poslije kirur{kog od-
stranjenja tumora. Uzorci seruma sakupljeni su od pacijenata s dijagnozom glioblastoma, meningeoma, neurinoma,
hemangioma, oligodendroglioma i astrocitoma, jedan tjedan prije i jedan tjedan nakon kirur{kog uklanjanja tumora.
Kvalitativna i kvantitativna analiza serumskih gangliozida provedena je tankoslojnom kromatografijom visoke mo}i
razlu~ivanja i laserskom denzitometrijom. Rezultati su pokazali razlike ukupnih koncentracija gangliozida u anali-
ziranim postoperativnim serumima u usporedbi s preoperativnim serumima. Gangliozidni obrazac preoperativnih i
postoperativnih seruma nije se zna~ajno razlikovao. Me|utim, uo~eno je postoperativno smanjenje udjela gangliozida
GD3 u serumima pacijenata u kojih je tumor potpuno uklonjen. Rezultati ovog istra`ivanja ukazuju da poredbena
kvantitativno-kvalitativna analiza preoperativnih i postoperativnih serumskih gangliozida mo`e pru`iti korisne podat-
ke o tumorskoj progresiji, uspje{nosti kirur{kog postupka i prognozi.
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